Protein Tyrosine Phosphatase PRL-3 (PTP4A3), belonging to the PRL family, has surfaced as a noteworthy participant in cancer signaling routes. Its irregularities have been linked to multiple phases of cancer advancement, such as metastasis and angiogenesis. This piece explores the architecture, operation, control, and medical relevance of PRL-3, illuminating its prospects as a target for cancer therapy.
HTML PDFShare this article
Journal of Cancer Clinical Trials received 95 citations as per Google Scholar report
